ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interferons"

  • Abstract Number: 2565 • 2016 ACR/ARHP Annual Meeting

    Common Biomarker Elevations in Idiopathic Pulmonary Fibrosis and Rheumatoid Arthritis-Associated Interstitial Lung Disease

    Karen Fernandez1, Tracy Doyle2, Lisa Harlow3, Ivan O. Rosas4 and Dana P. Ascherman5, 1Rheumatology, University of Miami Miller School of Medicine, Miami, FL, 2Medicine/Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, 3Rheumatology and Clinical Immunology, University of Miami Miller School of Medicine, Miami, FL, 4BWH - Pulmonary, Brigham and Women's Hospital, Boston, MA, 5Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL

    Background/Purpose:  Interstitial lung disease (ILD) is an extra-articular manifestation of rheumatoid arthritis (RA) which contributes to increased morbidity and mortality. Clinico-epidemiological data indicate some overlap…
  • Abstract Number: 2810 • 2016 ACR/ARHP Annual Meeting

    Correlates of Spontaneous Cytokine Production in Individuals Undergoing Interferon-Gamma Release Assay Testing

    Grant Hughes1, Christian Lood2, Uche Obih1 and David Koelle1, 1University of Washington, Seattle, WA, 2Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA

    Background/Purpose: The interferon gamma (IFN-G) release assay (IGRA) estimates probability of latent TB infection (LTBI) based on IFN-G released by whole blood after 18h exposure…
  • Abstract Number: 2878 • 2016 ACR/ARHP Annual Meeting

    Major Lymphocyte Populations Share a Common Interferon Signature but Express Cell Type-Specific Interferon Pathway Genes in SLE

    Mikhail Olferiev1, Kyriakos A. Kirou2, David Fernandez3, Khalili Leila1, Dina Greenman1 and Mary K. Crow4, 1Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Rheumatology, New York Presbyterian - Cornell Campus - HSS, New York, NY, 4Department of Medicine, Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY

    Background/Purpose: All lymphocyte populations contribute to SLE pathogenesis, but little is known of the specific gene transcripts particularly involved in each cell type. Activation of…
  • Abstract Number: 3006 • 2016 ACR/ARHP Annual Meeting

    IFN-Gamma (IFNγ), IFNγ-Induced Chemokines and Other Biomarkers in Macrophage Activation Syndrome (MAS)

    Claudia Bracaglia1, Denise Pires Marafon2, Ivan Caiello2, Kathy de Graaf3, Florence Guilhot3, Walter Ferlin3, Sergio Davì4, Grant Schulert5, Angelo Ravelli4, Alexei Grom6, Robert Nelson3, Cristina de Min3 and Fabrizio De Benedetti1, 1Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Italy, 2Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Rome, Italy, 3NovImmune S.A., Geneva, Switzerland, 4Istituto Giannina Gaslini, Genoa, Italy, 5Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 6Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose:  Evidence in animals and humans points to a pivotal role of IFNγ in primary HLH. We have recently generated data in an animal model…
  • Abstract Number: 3220 • 2016 ACR/ARHP Annual Meeting

    Distinct Single Cell Gene Expression Signatures of Monocyte Subsets Differentiate Between TNF-Alpha Inhibitor Treatment Response Groups in Rheumatoid Arthritis

    Theresa L. Wampler Muskardin1, Wei Fan2, Zhongbo Jin3, Mark A. Jensen4, Jessica M. Dorschner3, Yogita Ghodke-Puranik3, Kerry Wright1, John M. Davis III5, Eric L. Matteson1, Clement Michet Jr.1, Thomas G. Mason II6, Scott T. Persellin7, Daniel Schaffer1, Betty Dicke1, Danielle Vsetecka3 and Timothy B. Niewold8, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, MN, 3Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, 4Department of Immunology and Division of Rheumatology, Mayo Clinic, Rochester, MN, 5Division of Rheumatology, Mayo Clinic, Rochester, MN, 6Division of Rheumatology - Department of Medicine, Mayo Clinic Rochester, Rochester, MN, 7Department of Rheumatology, Mayo Clinic Rochester, Rochester, MN, 8Rheumatology and Immunology, Mayo Clinic, Rochester, MN

    Background/Purpose: In rheumatoid arthritis (RA), initiating effective treatment as soon as possible within the so-called therapeutic “window of opportunity” is the strategy, and remission is…
  • Abstract Number: 761 • 2016 ACR/ARHP Annual Meeting

    Exposure-Response Analysis for Selection of Optimal Dosage Regimen of Anifrolumab in Patients with Systemic Lupus Erythematosus

    L Santiago1, B Wang2, P Brohawn2, L Wang2, G Illei2 and L Roskos2, 1MedImmune, Mountain View, CA, 2MedImmune, Gaithersburg, MD

    Background/Purpose: Anifrolumab is a fully human IgG1 monoclonal antibody directed against subunit 1 of the type I interferon–α receptor (IFNAR1) currently in development for the…
  • Abstract Number: 774 • 2016 ACR/ARHP Annual Meeting

    BIIB059, an Anti-BDCA2 Monoclonal Antibody, Demonstrates Acceptable Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects in a Phase 1 Study with Single Ascending Doses (SAD) in Healthy Volunteers

    David Martin, Lauren Stevenson, Pratapa Prasad, Karen Smirnakis, Amy Kao, Dania Rabah, Wenting Wang and Nathalie Franchimont, Biogen, Cambridge, MA

    Background/Purpose:  Type I interferons (IFN-I) are implicated in the pathogenesis of systemic lupus erythematosus (SLE). In SLE, immune complexes stimulate plasmacytoid dendritic cells (pDCs) to…
  • Abstract Number: 792 • 2016 ACR/ARHP Annual Meeting

    Systemic Lupus Erythematosus (SLE) Responder Index [SRI(4)] Response Is Associated with Global Benefit in Patients with Moderate to Severe SLE

    R Furie1, L Wang2, J Drappa2 and G Illei2, 1Northwell Health, Great Neck, NY, 2MedImmune, Gaithersburg, MD

    Background/Purpose: Post-hoc analysis of two Phase III studies of belimumab1 showed that an SRI(4) response is associated with clinically meaningful benefits, irrespective of treatment assignment.…
  • Abstract Number: 864 • 2016 ACR/ARHP Annual Meeting

    Takayasu Arteritis Developed over the Age of 40 Has Lower Levels of Interferon Gamma and Interleukin 17 at Disease Onset and Fewer Subsequent Relapses

    Shoichi Fukui1, Naoki Iwamoto2, Toshimasa Shimizu2, Masataka Umeda2, Ayako Nishino3, Yoshiro Horai2, Tomohiro Koga4, Shin-ya Kawashiri5, Kunihiro Ichinose1, Yasuko Hirai2, Mami Tamai1, Hideki Nakamura5, Tomoki Origuchi6, Kiyoshi Migita7, Yukitaka Ueki8 and Atsushi Kawakami9, 1Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Department of Immunology and Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, 3Department of Immunology and Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki Universit, Nagasaki, Japan, 4Unit of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 5Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 6Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan, 7Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Japan, 8Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Sasebo, Japan, 9Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

    Background/Purpose: The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis (TAK) include age at disease onset ≤ 40 years. We aimed…
  • Abstract Number: 1518 • 2016 ACR/ARHP Annual Meeting

    Immunoglobulin Binding Protein (BiP), an Antigen for CCP Sero-Positive Rheumatoid Arthritis Patients, Can Result in a False Positive Quantiferon-Gold Tuberculosis Test

    JoAnn Ball1, Kelsy Greenwald1, Atul A. Deodhar2 and Kevin L. Winthrop3, 1Rheumatology, Desert Medical Advances, Palm Desert, CA, 2Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, 3Oregon Health and Sciences University, Portland, OR

    Background/Purpose: Citrullinated BiP is a newly described target for cyclic citrullinated peptide(CCP).  BiP in both serum and synovial fluid is over-expressed in RA patients and…
  • Abstract Number: 1831 • 2016 ACR/ARHP Annual Meeting

    A Novel Graph Theoretic Approach Applied to Modular Repertoire Analysis Identifies a Dual Molecular Progression in Adult SLE Patients, with Distinct Interferon and Neutrophil Transcription Patterns

    Ilya Korsunski1, Noémie Jourde-Chiche2,3, Peter K. Gregersen1, Damien Chaussabel4, Laurent Chiche5 and Naomi I Maria6, 1Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, 2Vascular Research Center of Marseille, Aix-Marseille Univ., Vascular Research Center of Marseille, Marseille, France, 3Nephrology, AP-HM, Department of Nephrology, CHU Conception, Marseille, France, 4Translational Medicine, Sidra Medical and Research Center, Doha, Qatar, 5internal medicine, Hopital Europeen, Marseille, France, 6Center for Autoimmune and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY

    Background/Purpose:  Gene expression studies support a pivotal role for type I interferon (IFN) in SLE. Previous work using a modular repertoire analysis based on co-clustered…
  • Abstract Number: 1828 • 2015 ACR/ARHP Annual Meeting

    Target Modulation of a Type I Interferon Gene Signature and Pharmacokinetics of Anifrolumab in a Phase IIb Study of Patients with Moderate to Severe Systemic Lupus Erythematosus

    Philip Brohawn1, Lingning Santiago2, Chris Morehouse1, Brandon Higgs1, Gabor Illei1 and Koustubh Ranade1, 1MedImmune, Gaithersburg, MD, 2MedImmune, Mountain View, CA

    Background/Purpose: Anifrolumab is a fully human IgG1 monoclonal antibody directed against subunit 1 of the type I interferon receptor (IFNAR1). Anifrolumab blocks the binding of…
  • Abstract Number: 2072 • 2015 ACR/ARHP Annual Meeting

    Mitochondrial Reactive Oxygen Species Modulate Autoimmunity in Systemic Lupus Erythematosus

    Luz P. Blanco1, Christian Lood2, Monica Purmalek3, Suk See DeRavin4, Carolyne K. Smith3, Carmelo Carmona-Rivera3, Harry Malech4, Jeffrey Ledbetter5, Keith B. Elkon6 and Mariana J. Kaplan1, 1Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Internal Medicine, University of Washington, Seattle, WA, 3Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 4NIAID/NIH, Bethesda, MD, 5University of Washington, Seattle, WA, 6Department of Medicine & Immunology, University of Washington, Seattle, WA

    Background/Purpose: Dysregulation in the formation of neutrophil extracellular traps (NETs) may contribute to modification and externalization of autoantigens and to organ damage in diverse autoimmune…
  • Abstract Number: 2073 • 2015 ACR/ARHP Annual Meeting

    Mitochondrial ROS Is a Novel Regulator of Sting-Mediated Type I IFN Production By Governing Extrusion of Oxidized Mitochondrial DNA upon Neutrophil Extracellular Trap Formation.

    Christian Lood1, Luz P. Blanco2, Monica Purmalek3, Carolyne K. Smith3, Carmelo Carmona-Rivera3, Jeffrey Ledbetter4, Mariana J. Kaplan2 and Keith B. Elkon5, 1Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA, 2Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 3Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 4University of Washington, Seattle, WA, 5Division of Rheumatology, University of Washington, Seattle, WA

    Background/Purpose: Neutrophil extracellular trap generation (NETosis) is a reactive oxygen species (ROS)-dependent cell death pathway implicated in autoimmune disorders such as systemic lupus erythematosus (SLE).…
  • Abstract Number: 2433 • 2015 ACR/ARHP Annual Meeting

    Anti Interferon-Gamma (IFNg) Monoclonal Antibody Treatment in a Child with NLRC4-Related Disease and Severe Hemophagocytic Lymphohistiocytosis (HLH)

    Claudia Bracaglia1, Giusi Prencipe1, Antonio Gatto2, Manuela Pardeo1, Geneviève Lapeyre3, Luigi Raganelli1, Emiliano Marasco2, Antonella Insalaco2, Walter Ferlin3, Robert Nelson3, Cristina de Min3 and Fabrizio De Benedetti1, 1Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, 2Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, 3NovImmune S.A., Geneva, Switzerland

    Background/Purpose: Animal and humans data suggest that IFNγ plays a pathogenic role in HLH. A pilot trial in primary HLH with NI-0501, an anti-IFNγ monoclonal…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology